文献速递角膜与眼表疾病

SARS-CoV-2 mRNA疫苗接种后角膜内皮移植排斥反应的特征

Characteristics of endothelial corneal transplant rejection following immunisation with SARS-CoV-2 messenger RNA vaccine.
PubMed 文献 · Br J Ophthalmol · 2021-04-28

本文报告两例在接受SARS-CoV-2 mRNA疫苗BNT162b2接种后发生角膜内皮移植排斥的病例:一例为66岁女性Fuchs内皮角膜营养不良患者,单眼DMEK移植后14天接种疫苗,7天后出现内皮移植排斥;另一例为83岁女性Fuchs内皮角膜营养不良患者,双眼DMEK移植后3年和6年,在第二剂疫苗接种后3周双眼同时发生急性内皮排斥。两例均经局部皮质类固醇治疗成功。作者认为这是首报COVID-19免疫接种后角膜移植排斥的时间关联及任何免疫接种后DMEK排斥。

要点

  • 两例DMEK移植排斥均发生在SARS-CoV-2 mRNA疫苗BNT162b2接种后,时间关联分别为接种后7天和3周。
  • 两例排斥均经局部皮质类固醇治疗成功。
  • 临床医生和患者应知晓疫苗接种可能与角膜移植排斥相关,可考虑在计划非紧急角膜移植前接种疫苗。

核心结论

  • 作者认为这是首报COVID-19免疫接种后角膜移植排斥的时间关联及任何免疫接种后DMEK排斥,并假设同种异体反应可能由疫苗接种后的宿主抗体反应引发。

研究设计与样本

  • 病例报告,报告两例接受SARS-CoV-2 mRNA疫苗BNT162b2接种后发生角膜内皮移植排斥的病例。

主要发现

  • 66岁女性Fuchs内皮角膜营养不良患者单眼DMEK移植后14天接种BNT162b2,接种后7天出现内皮移植排斥症状和体征。
  • 83岁女性Fuchs内皮角膜营养不良患者双眼DMEK移植后3年和6年,在BNT162b2第二剂接种后3周双眼同时发生急性内皮排斥。
  • 两例排斥均经局部皮质类固醇治疗成功。

关键数值与推荐

  • 两例排斥均经局部皮质类固醇治疗成功。

临床怎么用

  • 临床医生和患者应知晓疫苗接种可能与角膜移植排斥相关。
  • 可考虑在计划非紧急角膜移植前接种疫苗。
  • 应告知患者需要紧急复查的症状和体征,以便对确诊的排斥发作早期治疗。

局限性

  • 本文为两例病例报告,未报告样本量、P值等统计指标。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIM: We report two cases of endothelial corneal allograft rejection following immunisation with SARS-CoV-2 messenger RNA (mRNA) vaccine BNT162b2 and describe the implications for management of transplant recipients postvaccination for COVID-19. METHODS: A 66-year-old woman with Fuchs endothelial corneal dystrophy (FECD) and a unilateral Descemet's membrane endothelial keratoplasty (DMEK) transplant received COVID-19 mRNA vaccine BNT162b2 14 days post-transplant. Seven days later, she presented with symptoms and signs of endothelial graft rejection. An 83-year-old woman with bilateral DMEK transplants for FECD 3 and 6 years earlier developed simultaneous acute endothelial rejection in both eyes, 3 weeks post second dose of COVID-19 mRNA vaccine BNT162b2. Rejection in both cases was treated successfully with topical corticosteroids. CONCLUSIONS: We believe this is the first report of temporal association between corneal transplant rejection following immunisation against COVID-19 and the first report of DMEK rejection following any immunisation. We hypothesise that the allogeneic response may have been initiated by the host antibody response following vaccination. Clinicians and patients should be aware of the potential of corneal graft rejection associated with vaccine administration and may wish to consider vaccination in advance of planned non-urgent keratoplasties. Patients should be counselled on the symptoms and signs that require urgent review to allow early treatment of any confirmed rejection episode.

来源:Br J Ophthalmol,查看原文。版权归原作者所有。

引用

  1. Phylactou M, Li JO, Larkin DFP, et al. Characteristics of endothelial corneal transplant rejection following immunisation with SARS-CoV-2 messenger RNA vaccine. Br J Ophthalmol. 2021. PMID: 33910885. doi:10.1136/bjophthalmol-2021-319338

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。